{"id":"tacrolimus-bid","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Tremor"},{"rate":"5-10%","effect":"Hypertension"}]},"_chembl":{"chemblId":"CHEMBL3989887","moleculeType":"Small molecule","molecularWeight":"822.05"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting calcineurin, tacrolimus prevents the transcription of interleukin-2 (IL-2), a cytokine that promotes T-lymphocyte proliferation and activation. This results in a decrease in the immune response and reduces the risk of organ rejection in transplant patients.","oneSentence":"Tacrolimus is an immunosuppressive drug that works by inhibiting calcineurin, which is necessary for the activation of T-lymphocytes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:17.380Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis of organ rejection in patients receiving allogeneic organ transplants"}]},"trialDetails":[{"nctId":"NCT01861106","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-24","conditions":"GATA2, Immunodeficiency, MDS","enrollment":144},{"nctId":"NCT06751992","phase":"PHASE4","title":"Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-03-17","conditions":"Kidney Transplant Recipients, Old Age","enrollment":92},{"nctId":"NCT06354179","phase":"PHASE4","title":"Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)","status":"RECRUITING","sponsor":"University Hospital, Limoges","startDate":"2025-04-15","conditions":"Liver Transplantation, Immunosuppression","enrollment":162},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT05622318","phase":"PHASE2","title":"De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-08-29","conditions":"Graft-versus-host Disease","enrollment":56},{"nctId":"NCT03970096","phase":"PHASE2","title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-11-19","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT06638879","phase":"PHASE1","title":"Tacrolimus Toothpaste for Management of Oral Chronic Graft vs. Host Disease (cGVHD)","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2024-09-17","conditions":"Chronic Graft Versus Host Disease Oral","enrollment":7},{"nctId":"NCT05707377","phase":"PHASE2, PHASE3","title":"A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeOne Medicines","startDate":"2023-04-17","conditions":"Primary Membranous Nephropathy","enrollment":178},{"nctId":"NCT02333162","phase":"PHASE1","title":"Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2014-12-05","conditions":"Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT06692426","phase":"PHASE1","title":"Trial of Cell Based Therapy for DMD","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2025-03-20","conditions":"Duchenne Muscular Dystrophy","enrollment":8},{"nctId":"NCT06055608","phase":"PHASE2","title":"Advancing Transplantation Outcomes in Children","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-05-22","conditions":"Kidney Transplant","enrollment":200},{"nctId":"NCT07228624","phase":"PHASE2","title":"Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-02-04","conditions":"Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":50},{"nctId":"NCT00544466","phase":"PHASE1, PHASE2","title":"Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2006-07-31","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":75},{"nctId":"NCT07359859","phase":"PHASE2","title":"A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-01-20","conditions":"Hematologic Malignancies","enrollment":40},{"nctId":"NCT05027945","phase":"PHASE2","title":"A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-23","conditions":"Immunodeficiency, Hematopoietic Stem Cell Transplantation","enrollment":54},{"nctId":"NCT02861417","phase":"PHASE2","title":"Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-08-05","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome","enrollment":204},{"nctId":"NCT03467386","phase":"PHASE1","title":"Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2018-03-19","conditions":"Acute Myeloid Leukemia","enrollment":56},{"nctId":"NCT05490511","phase":"PHASE1","title":"Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus","status":"COMPLETED","sponsor":"Indiana University","startDate":"2022-10-31","conditions":"CBD, Transplant Complication, Kidney Disease, Chronic","enrollment":57},{"nctId":"NCT07406932","phase":"NA","title":"A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome","status":"NOT_YET_RECRUITING","sponsor":"China-Japan Friendship Hospital","startDate":"2026-02-01","conditions":"Antisynthetase Syndrome, Interstitial Lung Disease (ILD)","enrollment":80},{"nctId":"NCT03656926","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":169},{"nctId":"NCT02891603","phase":"PHASE1, PHASE2","title":"A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-06-08","conditions":"Graft Vs Host Disease, GVHD","enrollment":40},{"nctId":"NCT00882895","phase":"PHASE2","title":"Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2009-05-05","conditions":"Lymphoma, Non-Hodgkin","enrollment":18},{"nctId":"NCT03032783","phase":"PHASE2","title":"A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2017-01-31","conditions":"Hematopoietic and Lymphoid Cell Neoplasm","enrollment":51},{"nctId":"NCT06832189","phase":"PHASE1","title":"EVR and EPO for Liver Transplant Tolerance","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-01-21","conditions":"Liver Transplant","enrollment":20},{"nctId":"NCT04262843","phase":"PHASE2","title":"Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-02-07","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome","enrollment":33},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT02081755","phase":"PHASE4","title":"Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Baylor Research Institute","startDate":"2014-03","conditions":"Carcinoma, Hepatocellular","enrollment":336},{"nctId":"NCT03842696","phase":"PHASE1, PHASE2","title":"Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-02-04","conditions":"Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase","enrollment":43},{"nctId":"NCT07368673","phase":"PHASE4","title":"Comparative Effectiveness of Ruxolitinib Monotherapy Versus Its Combination With Tacrolimus and Corticosteroids in the Management of Vitiligo: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Dow University of Health Sciences","startDate":"2025-04-06","conditions":"Vitiligo","enrollment":120},{"nctId":"NCT07367932","phase":"PHASE4","title":"Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-02","conditions":"Dermatitis, Atopic, Eczema","enrollment":30},{"nctId":"NCT06084780","phase":"PHASE2","title":"Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)","status":"NOT_YET_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2026-02","conditions":"Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum, Pseudomyxoma Peritonei","enrollment":20},{"nctId":"NCT07307534","phase":"NA","title":"Nevus Removal vs. Conservative Treatment in Halo Nevus With Vitiligo: A Randomized Study","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2026-01-20","conditions":"Vitiligo, Halo Nevus","enrollment":60},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT04370301","phase":"PHASE2","title":"Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-02-09","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":20},{"nctId":"NCT04022239","phase":"PHASE1, PHASE2","title":"Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-03-13","conditions":"Hematopoietic and Lymphoid System Neoplasm","enrollment":25},{"nctId":"NCT03674411","phase":"PHASE2","title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2019-01-02","conditions":"Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia","enrollment":22},{"nctId":"NCT07249346","phase":"PHASE2","title":"Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Hannah Choe, MD","startDate":"2026-06-01","conditions":"Leukemia, Myelodysplasia, Chronic Myelomonocytic Leukemia","enrollment":124},{"nctId":"NCT07302776","phase":"PHASE1","title":"TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-02","conditions":"GVHD, Hematopoietic Cell Transplantation (HCT), Acute Myeloid Leukemia (AML)","enrollment":50},{"nctId":"NCT05088356","phase":"PHASE1","title":"Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-09-07","conditions":"Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia","enrollment":60},{"nctId":"NCT03979365","phase":"PHASE4","title":"Envarsus XR Compared to Immediate Release Tacrolimus","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-07-18","conditions":"Kidney Transplant Recipients","enrollment":261},{"nctId":"NCT04104438","phase":"PHASE4","title":"Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant","status":"COMPLETED","sponsor":"Fady M Kaldas, M.D., F.A.C.S.","startDate":"2021-01-15","conditions":"Asses Immunosuppression Modulation on Renal Recovery Post LT","enrollment":71},{"nctId":"NCT03247088","phase":"PHASE1, PHASE2","title":"Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-07-30","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":74},{"nctId":"NCT06126380","phase":"PHASE2","title":"Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Eledon Pharmaceuticals","startDate":"2023-10-25","conditions":"Kidney Transplant Rejection","enrollment":132},{"nctId":"NCT04477629","phase":"PHASE2","title":"Belatacept in De Novo Heart Transplantation","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2020-08-06","conditions":"Heart Transplantation","enrollment":12},{"nctId":"NCT02882828","phase":"PHASE4","title":"PK Assessment of Tacrolimus Exposure Before and After a Switch From Twice Daily Immediate-release (Prograf®) to Once-daily Prolonged Release Tacrolimus (Envarsus®)","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2016-10","conditions":"Allograft","enrollment":134},{"nctId":"NCT07239128","phase":"EARLY_PHASE1","title":"Photobiomodulation in Combination With Topical Cyclosporine A or Tacrolimus","status":"COMPLETED","sponsor":"University of Seville","startDate":"2024-05-01","conditions":"Dry Eye Disease (DED)","enrollment":160},{"nctId":"NCT06195891","phase":"PHASE1","title":"Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-05-24","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":33},{"nctId":"NCT04773392","phase":"PHASE4","title":"Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2021-11-23","conditions":"Kidney Transplantation, Kidney Transplant Rejection","enrollment":20},{"nctId":"NCT06128070","phase":"PHASE2","title":"Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-07-16","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":40},{"nctId":"NCT05031897","phase":"PHASE2","title":"Two Step Haplo With Radiation Conditioning","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2021-10-25","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult T-Cell Leukemia/Lymphoma","enrollment":63},{"nctId":"NCT01760655","phase":"PHASE2","title":"Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2012-12-24","conditions":"Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM","enrollment":62},{"nctId":"NCT05983770","phase":"PHASE2","title":"Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation","status":"COMPLETED","sponsor":"Eledon Pharmaceuticals","startDate":"2023-08-30","conditions":"Kidney Transplant Rejection","enrollment":127},{"nctId":"NCT03657342","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":62},{"nctId":"NCT03856216","phase":"PHASE2","title":"Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-28","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Lymphocytic Neoplasm","enrollment":15},{"nctId":"NCT03779854","phase":"PHASE2","title":"Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-08-29","conditions":"Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage","enrollment":68},{"nctId":"NCT03841097","phase":"PHASE4","title":"Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roy D. Bloom, MD","startDate":"2019-11-11","conditions":"Kidney Transplant; Complications","enrollment":60},{"nctId":"NCT04859946","phase":"PHASE2","title":"Itacitinib for the Prevention of Graft Versus Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-01-11","conditions":"Hematologic and Lymphocytic Disorder","enrollment":31},{"nctId":"NCT03816332","phase":"PHASE1","title":"Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-11-08","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":12},{"nctId":"NCT03373227","phase":"PHASE2","title":"Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2017-12-04","conditions":"Heart Transplant Rejection, Graft Failure, Compliance, Patient","enrollment":50},{"nctId":"NCT02630628","phase":"PHASE3","title":"Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2015-12-05","conditions":"Lupus Nephritis","enrollment":130},{"nctId":"NCT00552201","phase":"PHASE4","title":"TACrolimus in Renal Transplantation: Individualization by Pharmacogenetic","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2006-04","conditions":"Kidney Transplantation","enrollment":280},{"nctId":"NCT07162896","phase":"PHASE3","title":"Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Shalamar Institute of Health Sciences","startDate":"2026-06","conditions":"Atopic Dermatitis, Atopic Dermatitis (AD)","enrollment":66},{"nctId":"NCT03712878","phase":"PHASE2","title":"2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2018-09-19","conditions":"Hematopoietic and Lymphoid Cell Neoplasm","enrollment":10},{"nctId":"NCT05646992","phase":"PHASE2, PHASE3","title":"Uterus Transplantation to Treat Infertility","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-03-01","conditions":"Uterine Factor Infertility","enrollment":40},{"nctId":"NCT06287944","phase":"PHASE1","title":"225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-07-01","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":15},{"nctId":"NCT04669210","phase":"PHASE2","title":"PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT","status":"COMPLETED","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2020-11-03","conditions":"Graft-versus-host-disease, Stem Cell Transplant Complications, Acute Myeloid Leukemia","enrollment":128},{"nctId":"NCT06829719","phase":"NA","title":"TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-04-23","conditions":"Infection, Cancer, Rejection","enrollment":300},{"nctId":"NCT02446964","phase":"PHASE1","title":"Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2015-06-25","conditions":"Adult Acute Lymphoblastic Leukemia in Complete Remission, Acute Myeloid Leukemia in Remission, Previously Treated Myelodysplastic Syndrome","enrollment":31},{"nctId":"NCT06412497","phase":"PHASE2","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-06-05","conditions":"Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia","enrollment":60},{"nctId":"NCT02220985","phase":"PHASE2","title":"Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2015-02-03","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage","enrollment":84},{"nctId":"NCT01871441","phase":"PHASE2","title":"Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2013-05-17","conditions":"Malignant Neoplasm","enrollment":4},{"nctId":"NCT03828019","phase":"PHASE3","title":"Adalimumab vs. Conventional Immunosuppression for Uveitis Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2019-09-16","conditions":"Uveitis","enrollment":227},{"nctId":"NCT06233591","phase":"PHASE2","title":"Evaluating LP-10 in Subjects With OLP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lipella Pharmaceuticals, Inc.","startDate":"2024-07-01","conditions":"Oral Lichen Planus","enrollment":24},{"nctId":"NCT06960824","phase":"","title":"Real-word Study of the de NOVO Extended-release tacrolimuS in Kidney Transplantation Using an ARTificial Intelligence","status":"NOT_YET_RECRUITING","sponsor":"Chiesi SAS","startDate":"2025-05","conditions":"Chronic Renal Disease","enrollment":165},{"nctId":"NCT01532635","phase":"PHASE2","title":"A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2012-03","conditions":"Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia","enrollment":4},{"nctId":"NCT00429143","phase":"PHASE1, PHASE2","title":"A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2006-01","conditions":"Hematologic Malignancies","enrollment":27},{"nctId":"NCT02548468","phase":"PHASE1","title":"Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2015-11-20","conditions":"Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Stage IIB Mycosis Fungoides and Sezary Syndrome","enrollment":""},{"nctId":"NCT01341301","phase":"PHASE2","title":"Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2010-05","conditions":"Hematologic Malignancy","enrollment":25},{"nctId":"NCT01982682","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2013-11-04","conditions":"Hematopoietic/Lymphoid Cancer","enrollment":41},{"nctId":"NCT02566304","phase":"PHASE2","title":"Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2015-11-13","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Aplastic Anemia","enrollment":35},{"nctId":"NCT03689075","phase":"PHASE4","title":"Extended Release Versus Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce Allosensitisation","status":"TERMINATED","sponsor":"Imperial College Healthcare NHS Trust","startDate":"2018-11-01","conditions":"Kidney Transplant Failure, Allosensitization, Immunosuppression","enrollment":35},{"nctId":"NCT02711826","phase":"PHASE1, PHASE2","title":"Treg Therapy in Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-09-20","conditions":"Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant","enrollment":32},{"nctId":"NCT05607901","phase":"PHASE2","title":"A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus Hydrocortisone","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-10-28","conditions":"Dermatologic Disease","enrollment":100},{"nctId":"NCT04646356","phase":"PHASE2","title":"Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2020-10-20","conditions":"Hereditary Hemorrhagic Telangiectasia, Epistaxis Nosebleed","enrollment":10},{"nctId":"NCT03823768","phase":"PHASE4","title":"Envarsus Neurotoxicity Burden in Liver Transplant Patients","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2020-01-31","conditions":"Neurotoxicity, Liver Transplant; Complications","enrollment":30},{"nctId":"NCT01163357","phase":"PHASE1","title":"Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2011-01-28","conditions":"Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia","enrollment":18},{"nctId":"NCT04665310","phase":"PHASE4","title":"Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2018-09-01","conditions":"Kidney Disease, End-Stage, Donor Specific Antibodies, Acute Rejection of Renal Transplant","enrollment":46},{"nctId":"NCT04469842","phase":"EARLY_PHASE1","title":"Early Use of Long-acting Tacrolimus in Lung Transplant Recipients","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-12-01","conditions":"Lung Transplant; Complications","enrollment":48},{"nctId":"NCT04838288","phase":"PHASE4","title":"Cognitive Outcomes in Stable Renal Transplant Patients Switched FromTacrolimus to Envarsus XR™","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-06-22","conditions":"Renal Transplant","enrollment":60},{"nctId":"NCT03555448","phase":"PHASE4","title":"Once Daily Immunosuppression Regimen","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2018-06-04","conditions":"Kidney Transplant; Complications","enrollment":51},{"nctId":"NCT03577431","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at MGH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-29","conditions":"Liver Transplant","enrollment":9},{"nctId":"NCT02723591","phase":"PHASE4","title":"To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-09-09","conditions":"Kidney Transplantation","enrollment":599},{"nctId":"NCT05655273","phase":"PHASE4","title":"Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"University Health Network, Toronto","startDate":"2024-01-01","conditions":"Liver Transplant Rejection, Immune System Suppression","enrollment":40},{"nctId":"NCT06719024","phase":"PHASE2, PHASE3","title":"Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus","status":"RECRUITING","sponsor":"Hospital Authority, Hong Kong","startDate":"2024-11-29","conditions":"Vitiligo","enrollment":20},{"nctId":"NCT02921789","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-05-22","conditions":"Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)","enrollment":67},{"nctId":"NCT01614665","phase":"PHASE2","title":"A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2012-04-03","conditions":"Heart Transplantation, Kidney Transplantation, Liver Transplantation","enrollment":44},{"nctId":"NCT02147938","phase":"","title":"A Study of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®)","status":"COMPLETED","sponsor":"Astellas Pharma S.A.S.","startDate":"2014-07-17","conditions":"Renal Transplantation","enrollment":578},{"nctId":"NCT01371344","phase":"PHASE4","title":"A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients","status":"TERMINATED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2011-06-24","conditions":"Heart Transplantation, Kidney Transplantation, Liver Transplantation","enrollment":47},{"nctId":"NCT02268201","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule","status":"TERMINATED","sponsor":"Astellas Pharma China, Inc.","startDate":"2013-07-23","conditions":"Kidney Transplant Recipients","enrollment":17},{"nctId":"NCT03644485","phase":"PHASE4","title":"Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2018-10-21","conditions":"Kidney Transplant","enrollment":284}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prograf, Tacrocell"],"phase":"phase_3","status":"active","brandName":"Tacrolimus BID","genericName":"Tacrolimus BID","companyName":"Rabin Medical Center","companyId":"rabin-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tacrolimus is an immunosuppressive drug that works by inhibiting calcineurin, which is necessary for the activation of T-lymphocytes. Used for Prophylaxis of organ rejection in patients receiving allogeneic organ transplants.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}